Detail akcie Nordic Nanov online

Business Summary: Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. It has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.
Financial Summary: BRIEF: For the three months ended 31 March 2020, Nordic Nanovector ASA revenues was not reported. Net loss increased 2% to NOK93.7M. Higher net loss reflects Other operating expenses increase of 54% to NOK102.4M (expense), Depreciation increase from NOK1.1M to NOK3.7M (expense), Foreign Exchange Gain/Loss–Non-Busine decrease from NOK371K (income) to NOK1.2M (expense).